Ajovy Injection
NDC Package 51759-202-22

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Ajovy (fremanezumab-vfrm) injection is a medication used to help prevent migraine. This formulation utilizes a injection delivery system. Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 51759-202 and is authorized under FDA application BLA761089.

Identification & Billing

NDC Package Code
51759-202-22
Package Description
3 CONTAINER in 1 CARTON / 1.5 mL in 1 CONTAINER
Product Code
51759-202
11-Digit Billing Format
51759020222
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ajovy
Non-Proprietary Name
Fremanezumab-vfrm
Substance Name
Fremanezumab
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
FREMANEZUMAB 225 mg/1.5mL
Usage Information
This medication is used to help prevent migraine. This medication may work by changing the amounts of certain natural substances in the brain. Fremanezumab-vfrm belongs to a class of drugs known as monoclonal antibodies. Preventing frequent migraine attacks can help improve your ability to concentrate and do your usual tasks.

Regulatory & Marketing

Labeler Name
Teva Pharmaceuticals Usa, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761089
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
03-29-2020
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J3031
Source: PDAC
INJECTION, FREMANEZUMAB-VFRM, 1 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF-ADMINISTERED)
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51759-202). Click a package code to view its specific billing and regulatory data.

51759-202-10
1 CONTAINER in 1 CARTON / 1.5 mL in 1 CONTAINER
51759-202-11
1 CONTAINER in 1 CARTON / 1.5 mL in 1 CONTAINER

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51759-202-22 identifies a specific commercial package of 3 container in 1 carton / 1.5 ml in 1 container of Ajovy, a human prescription drug labeled by Teva Pharmaceuticals Usa, Inc.. This injection is formulated for subcutaneous use and contains fremanezumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on March 29, 2020. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to help prevent migraine. This medication may work by changing the amounts of certain natural substances in the brain. Fremanezumab-vfrm belongs to a class of drugs known as monoclonal antibodies. Preventing frequent migraine attacks can help improve your ability to concentrate and do your usual tasks.

How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51759020222. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51759-202-22
11-Digit CMS (5-4-2)
51759-0202-22

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.